Two Seas Capital LP Boosts Stake in Indivior PLC $INDV

Two Seas Capital LP boosted its position in Indivior PLC (NASDAQ:INDV) by 5.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 3,671,072 shares of the company’s stock after purchasing an additional 191,579 shares during the period. Indivior comprises about 1.5% of Two Seas Capital LP’s portfolio, making the stock its 8th biggest holding. Two Seas Capital LP’s holdings in Indivior were worth $131,608,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of INDV. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Indivior in the fourth quarter valued at $82,687,000. Assenagon Asset Management S.A. bought a new position in shares of Indivior during the 2nd quarter worth $63,224,000. Newtyn Management LLC purchased a new stake in Indivior in the 2nd quarter worth about $53,577,000. Hennion & Walsh Asset Management Inc. purchased a new stake in Indivior in the 2nd quarter worth about $14,781,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Indivior in the 2nd quarter valued at about $7,988,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on INDV. Craig Hallum reiterated a “buy” rating and issued a $53.00 price objective on shares of Indivior in a research note on Tuesday, August 4th. Weiss Ratings lowered Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Barclays decreased their target price on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 5th. Finally, Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Indivior has a consensus rating of “Buy” and a consensus target price of $45.17.

Indivior Trading Down 0.3%

Indivior stock traded down $0.09 on Tuesday, hitting $35.90. 2,390,473 shares of the stock traded hands, compared to its average volume of 2,173,062. The business’s fifty day simple moving average is $36.63 and its 200 day simple moving average is $36.44. The firm has a market cap of $4.24 billion, a P/E ratio of 12.87 and a beta of 0.87. Indivior PLC has a 1 year low of $22.78 and a 1 year high of $42.81.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. The company had revenue of $343.00 million during the quarter. As a group, analysts predict that Indivior PLC will post 3.66 earnings per share for the current year.

Indivior Announces Dividend

The business also recently declared a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be paid a $8.13 dividend. The ex-dividend date is Friday, October 30th.

Insider Activity at Indivior

In other Indivior news, insider Christian Heidbreder sold 18,586 shares of Indivior stock in a transaction on Friday, July 10th. The stock was sold at an average price of $41.14, for a total transaction of $764,628.04. Following the completion of the transaction, the insider owned 209,337 shares in the company, valued at approximately $8,612,124.18. The trade was a 8.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson bought 1,500 shares of the company’s stock in a transaction on Thursday, August 27th. The stock was bought at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the acquisition, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. This represents a 5.74% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 0.74% of the company’s stock.

Indivior Company Profile

Indivior PLC (NASDAQ: INDV) is a specialty pharmaceutical company focused on developing and commercializing treatments for substance use disorders and serious mental health conditions. The company’s primary focus is opioid use disorder, with products designed to support patients through medication-assisted treatment and recovery.

Indivior’s portfolio includes Sublocade, an extended-release injectable formulation of buprenorphine; Suboxone, a buprenorphine and naloxone product available in sublingual formulations; and Perseris, an extended-release injectable formulation of risperidone for schizophrenia.